Patents by Inventor Barry S. Coller
Barry S. Coller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11192889Abstract: Tetrahydronaphthyridines of formula are disclosed. These compounds selectively inhibit ?V?3 without activating the ?V?3 receptor. They are useful for treating osteoporosis, acute myelogenous leukemia, sickle cell disease, focal segmental glomerulosclerosis, fibrosis, supravalvular aortic stenosis associated with Williams syndrome, tumors expressing ?V?3, tumor metastasis, bone resorption, T-cell lymphoma, retinal disease, age-related macular degeneration, diabetic retinitis, and herpes simplex virus infection. They may also be used for inhibiting tumor angiogenesis.Type: GrantFiled: July 5, 2017Date of Patent: December 7, 2021Assignee: THE ROCKEFELLER UNIVERSITYInventors: Barry S. Coller, Marta Filizola, Michael Andrew Foley
-
Publication number: 20200181138Abstract: Tetrahydronaphthyridines of formula are disclosed. These compounds selectively inhibit ?V?3 without activating the ?V?3 receptor. They are useful for treating osteoporosis, acute myelogenous leukemia, sickle cell disease, focal segmental glomerulosclerosis, fibrosis, supravalvular aortic stenosis associated with Williams syndrome, tumors expressing ?V?3, tumor metastasis, bone resorption, T-cell lymphoma, retinal disease, age-related macular degeneration, diabetic retinitis, and herpes simplex virus infection. They may also be used for inhibiting tumor angiogenesis.Type: ApplicationFiled: July 5, 2017Publication date: June 11, 2020Applicants: The Rockefeller University, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Barry S. COLLER, Marta FILIZOLA, Michael Andrew FOLEY
-
Patent number: 10450375Abstract: The present invention relates to methods of treating sickle cell disease comprising reducing, in a subject in need of such treatment, the adherence between sickle RBCs and leukocytes. It is based, at least in part, on the discovery that leukocytes play a direct role in the initiation of venular occlusion. The present invention further provides for methods for identifying agents which decrease SS-RBC/leukocyte adherence and for animal models which may be used to further elucidate the mechanism of vaso-occlusion in sickle cell crises.Type: GrantFiled: November 3, 2004Date of Patent: October 22, 2019Assignee: Icahn School of Medicine at Mount SinaiInventors: Paul S. Frenette, Barry S. Coller, Aslihan Turhan
-
Publication number: 20190153101Abstract: The present invention relates to methods of treating sickle cell disease comprising reducing, in a subject in need of such treatment, the adherence between sickle RBCs and leukocytes. It is based, at least in part, on the discovery that leukocytes play a direct role in the initiation of venular occlusion. The present invention further provides for methods for identifying agents which decrease SS-RBC/leukocyte adherence and for animal models which may be used to further elucidate the mechanism of vaso-occlusion in sickle cell crises.Type: ApplicationFiled: January 25, 2019Publication date: May 23, 2019Inventors: Paul S. Frenette, Barry S. Coller, Aslihan Turhan
-
Patent number: 9532989Abstract: The present invention relates to compounds of Formula P-I where the variables (e.g. R1, Y, A, R1, Ra, Ra?, Rb, Rb?, Rc, Rc?, Rd, Rd?, Re, or Re?) and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.Type: GrantFiled: June 4, 2015Date of Patent: January 3, 2017Assignees: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, THE ROCKEFELLER UNIVERSITYInventors: Barry S. Coller, Craig Thomas, Marta Filizola, Joshua McCoy, Wenwei Huang, Min Shen
-
Patent number: 9341637Abstract: A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.Type: GrantFiled: November 10, 2010Date of Patent: May 17, 2016Assignee: ACCUMETRICS INC.Inventors: Barry S. Coller, Dennis Durbin
-
Patent number: 9303044Abstract: The present invention relates to compounds and compositions of Formula P useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The definitions of variables A, B, R2, R3, R4, Ra, Ra?, Rb, Rb?, Rc, Rd, Rd?, Re, and Re? are provided in the disclosure. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.Type: GrantFiled: January 16, 2013Date of Patent: April 5, 2016Assignees: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE ROCKEFELLER UNIVERSITY, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Barry S. Coller, Craig Thomas, Marta Filizola, Joshua McCoy, Wenwei Huang, Min Shen, Jian-Kang Jiang
-
Publication number: 20150374697Abstract: The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.Type: ApplicationFiled: June 4, 2015Publication date: December 31, 2015Inventors: Barry S. Coller, Craig Thomas, Marta Filizola, Joshua McCoy, Wenwei Huang, Min Shen
-
Patent number: 9073945Abstract: The present invention relates to methods for the treatment or prophylaxis of thrombotic disorders comprising administration of alpha-IIB-beta-3 inhibitor compounds and compositions containing the compounds. The methods of the invention are useful for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.Type: GrantFiled: April 6, 2012Date of Patent: July 7, 2015Assignee: THE ROCKEFELLER UNIVERSITYInventors: Robert Blue, Barry S. Coller
-
Patent number: 9066948Abstract: The present invention relates to compounds of formula P-1 and related compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The definitions of A, Y, R1, R2, Ra, Ra?, Rb, Rb?, Rc, Rc?, Rd, Rd?, Re, and Re? are provided herein. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.Type: GrantFiled: July 15, 2011Date of Patent: June 30, 2015Assignees: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE ROCKEFELLER UNIVERSITY, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Barry S. Coller, Craig Thomas, Marta Filizola, Joshua McCoy, Wenwei Huang, Min Shen
-
Publication number: 20150050325Abstract: The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to a drug-eluting stent comprising said compounds and methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.Type: ApplicationFiled: January 16, 2013Publication date: February 19, 2015Applicant: The Rockefeller UniversityInventors: Barry S. Coller, Craig Thomas, Marta Filizola, Joshua McCoy, Wenwei Huang, Min Shen, Jian-Kang Jiang
-
Publication number: 20140234859Abstract: A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.Type: ApplicationFiled: September 19, 2013Publication date: August 21, 2014Applicant: ACCUMETRICS, INC.Inventors: Barry S. COLLER, Dennis Durbin
-
Patent number: 8574828Abstract: A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.Type: GrantFiled: September 7, 2010Date of Patent: November 5, 2013Assignee: Accumetrics, Inc.Inventors: Barry S Coller, Dennis Durbin
-
Publication number: 20130251761Abstract: The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.Type: ApplicationFiled: July 15, 2011Publication date: September 26, 2013Inventors: Barry S. Coller, Craig Thomas, Marta Filizola, Joshua Mccoy, Wenwei Huang, Min Shen
-
Publication number: 20120190645Abstract: The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention also relates to methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.Type: ApplicationFiled: April 6, 2012Publication date: July 26, 2012Inventors: Robert Blue, Barry S. Coller
-
Patent number: 8173661Abstract: The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention also relates to methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.Type: GrantFiled: November 8, 2007Date of Patent: May 8, 2012Assignee: The Rockefeller UniversityInventors: Robert Blue, Barry S. Coller
-
Publication number: 20110081657Abstract: A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.Type: ApplicationFiled: November 10, 2010Publication date: April 7, 2011Applicant: ACCUMETRICS, INC.Inventors: Barry S. COLLER, Dennis Durbin
-
Publication number: 20110065125Abstract: A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.Type: ApplicationFiled: September 7, 2010Publication date: March 17, 2011Applicant: ACCUMETRICS, INC.Inventors: Barry S. COLLER, Dennis Durbin
-
Patent number: 7790362Abstract: A method is provided of determining whether an individual has reduced ability to form platelet thrombi. An ADP platelet activator and one or platelet inhibitors are provided. At least one of the platelet inhibitors is Prostaglandin E1 (PGE1). An alternate signal transduction pathway is produced. A final concentration of ADP is 2 to 35 ?M and a final concentration of PGE1 is 2 to 30 nM, preferably 20 to 25 nM.Type: GrantFiled: July 6, 2004Date of Patent: September 7, 2010Assignee: Accumetrics, Inc.Inventors: Barry S. Coller, Dennis Durbin
-
Publication number: 20100150913Abstract: The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention also relates to methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.Type: ApplicationFiled: November 8, 2007Publication date: June 17, 2010Applicant: The Rockefeller UniversityInventors: Robert Blue, Barry S. Coller